Chemical kinetics for drug discovery to combat protein aggregation diseases

Trends in Pharmacological Sciences

Volumn 35, Issue 3, 2014, Pages 127-135

  Arosio, Paolo ^a   Vendruscolo, Michele ^a   Dobson, Christopher M ^a   Knowles, Tuomas P J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

aggregation kinetics; inhibition mechanism; neurodegenerative diseases; therapeutics

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; CHAPERONE; TAFAMIDIS;

ALZHEIMER DISEASE; BINDING AFFINITY; CHEMICAL REACTION KINETICS; DEGENERATIVE DISEASE; DRUG DEVELOPMENT; DRUG MECHANISM; ENTHALPY; HUMAN; IN VITRO STUDY; MOLECULAR MECHANICS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW;

AGGREGATION KINETICS; INHIBITION MECHANISM; NEURODEGENERATIVE DISEASES; THERAPEUTICS;

DRUG DISCOVERY; HUMANS; KINETICS; MODELS, MOLECULAR; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING; PROTEINS; PROTEOSTASIS DEFICIENCIES;

EID: 84896695581     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2013.12.005     Document Type: Review

References (79)

1. B.L. Bennett et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase Proc. Natl. Acad. Sci. U.S.A. 98 2001 13681 13686
2. B.J. Druker et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
3. Alzheimer's Association 2011 Alzheimer's disease facts and figures Alzheimers Dement. 7 2011 208 244
4. I.W. Hamley The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization Chem. Rev. 112 2012 5147 5192
5. F. Chiti, and C.M. Dobson Protein misfolding, functional amyloid, and human disease Annu. Rev. Biochem. 75 2006 333 366
6. J. Hardy, and D.J. Selkoe Medicine - the amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356
7. P.T. Lansbury, and H.A. Lashuel A century-old debate on protein aggregation and neurodegeneration enters the clinic Nature 443 2006 774 779
8. J. Hardy Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration Biochem. Soc. Trans. 33 2005 578 581
9. S. Campioni et al. A causative link between the structure of aberrant protein oligomers and their toxicity Nat. Chem. Biol. 6 2010 140 147
10. S.I. Cohen et al. Proliferation of Aβ42 aggregates occurs through a secondary nucleation mechanism Proc. Natl. Acad. Sci. U.S.A. 110 2013 9758 9763
11. D.J. Selkoe, and J. Hardy The search for an amyloid solution - response Science 298 2002 963 964
12. D.M. Walsh, and D.J. Selkoe Aβ Oligomers - a decade of discovery J. Neurochem. 101 2007 1172 1184
13. T.P.J. Knowles et al. An analytical solution to the kinetics of breakable filament assembly Science 326 2009 1533 1537
14. V.N. Uversky, and A.L. Fink Conformational constraints for amyloid fibrillation: the importance of being unfolded Biochim. Biophys. Acta 1698 2004 131 153
15. F. Chiti et al. Rationalization of the effects of mutations on peptide and protein aggregation rates Nature 424 2003 805 808
16. J. Adamcik et al. Understanding amyloid aggregation by statistical analysis of atomic force microscopy images Nat. Nanotechnol. 5 2010 423 428
17. F. Ferrone Analysis of protein aggregation kinetics Methods Enzymol. 309 1999 256 274
18. S. Frokjaer, and D.E. Otzen Protein drug stability: a formulation challenge Nat. Rev. Drug Discov. 4 2005 298 306
19. F.A. Ferrone et al. Kinetics of sickle hemoglobin polymerization. 2. A double nucleation mechanism J. Mol. Biol. 183 1985 611 631
20. F.A. Ferrone et al. Kinetics of sickle hemoglobin polymerization. 1. Studies using temperature-jump and laser photolysis techniques J. Mol. Biol. 183 1985 591 610
21. A. Aguzzi, and T. O'Connor Protein aggregation diseases: pathogenicity and therapeutic perspectives Nat. Rev. Drug Discov. 9 2010 237 248
22. S.I.A. Cohen et al. From macroscopic measurements to microscopic mechanisms of protein aggregation J. Mol. Biol. 421 2012 160 171
23. K.L. Sciarretta et al. Peptide-based inhibitors of amyloid assembly I. Kheterpal, R. Wetzel, Methods in Enzymology: Amyloid, Prions, and Other Protein Aggregates (Vol. 413, Part C) 2006 Academic Press 273 312
24. S.A. Sievers et al. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation Nature 475 2011 96 100
25. F.E. Cohen, and J.W. Kelly Therapeutic approaches to protein-misfolding diseases Nature 426 2003 905 909
26. H. Zhang et al. Studying the effects of chaperones on amyloid fibril formation Methods 53 2011 285 294
27. R. Pul et al. Antibody-based therapy in Alzheimer's disease Expert Opin. Biol. Ther. 11 2011 343 357
28. Y. Porat et al. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism Chem. Biol. Drug Des. 67 2006 27 37
29. D.E. Ehrnhoefer et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat. Struct. Mol. Biol. 15 2008 558 566
30. A. Abelein et al. Transient small molecule interactions kinetically modulate amyloid β peptide self-assembly FEBS Lett. 586 2012 3991 3995
31. S. Weggen et al. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol. Sci. 28 2007 536 543
32. 42 peptide J. Am. Chem. Soc. 134 2012 6625 6636
33. G. Forloni et al. Anti-amyloidogenic activity of tetracyclines: studies in vitro FEBS Lett. 487 2001 404 407
34. S.I. Yoo et al. Inhibition of amyloid peptide fibrillation by inorganic nanoparticles: functional similarities with proteins Angew. Chem. Int. Ed. Engl. 50 2011 5110 5115
35. C. Cabaleiro-Lago et al. Inhibition of amyloid β protein fibrillation by polymeric nanoparticles J. Am. Chem. Soc. 130 2008 15437 15443
36. M. Bartolini, and V. Andrisano Strategies for the inhibition of protein aggregation in human diseases Chembiochem 11 2010 1018 1035
37. T. Hard, and C. Lendel Inhibition of amyloid formation J. Mol. Biol. 421 2012 441 465
38. A. Rauk The chemistry of Alzheimer's disease Chem. Soc. Rev. 38 2009 2698 2715
39. R. Leon et al. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease Med. Res. Rev. 33 2013 139 189
40. C.E. Bulawa et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade Proc. Natl. Acad. Sci. U.S.A. 109 2012 9629 9634
41. S.M. Johnson et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency- approved drug J. Mol. Biol. 421 2012 185 203
42. T. Klabunde et al. Rational design of potent human transthyretin amyloid disease inhibitors Nat. Struct. Biol. 7 2000 312 321
43. X. Meng et al. Molecular mechanisms underlying the flavonoid-induced inhibition of α-synuclein fibrillation Biochemistry 48 2009 8206 8224
44. B. Mannini et al. Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers Proc. Natl. Acad. Sci. U.S.A. 109 2012 12479 12484
45. S. Sinha et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins J. Am. Chem. Soc. 133 2011 16958 16969
46. E. Gazit Mechanisms of amyloid fibril self-assembly and inhibition FEBS J. 272 2005 5971 5978
47. S.L. Shammas et al. Binding of the molecular chaperone αB-crystallin to Aβ amyloid fibrils inhibits fibril elongation Biophys. J. 101 2011 1681 1689
48. C.A. Waudby et al. The interaction of αB-crystallin with mature α-synuclein amyloid fibrils inhibits their elongation Biophys. J. 98 2010 843 851
49. J.R. Kumita et al. The extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar species J. Mol. Biol. 369 2007 157 167
50. P. Narayan et al. The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β(1-40) peptide Nat. Struct. Mol. Biol. 19 2012 79 83
51. G.M. Shankar et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory Nat. Med. 14 2008 837 842
52. S.M. Butterfield, and H.A. Lashuel Amyloidogenic protein membrane interactions: mechanistic insight from model systems Angew. Chem. Int. Ed. Engl. 49 2010 5628 5654
53. J. Bieschke et al. Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils Nat. Chem. Biol. 8 2012 93 101
54. G. Merlini, and V. Bellotti Molecular mechanisms of amyloidosis N. Engl. J. Med. 349 2003 583 596
55. M. Tanaka et al. The physical basis of how prion conformations determine strain phenotypes Nature 442 2006 585 589
56. S.I.A. Cohen et al. Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments J. Chem. Phys. 135 2011 065105
57. M.F. Bishop, and F.A. Ferrone Kinetics of nucleation-controlled polymerization - a perturbation treatment for use with a secondary pathway Biophys. J. 46 1984 631 644
58. B.Y. Feng et al. Small-molecule aggregates inhibit amyloid polymerization Nat. Chem. Biol. 4 2008 197 199
59. C. Lendel et al. Detergent-like interaction of Congo red with the amyloid β peptide Biochemistry 49 2010 1358 1360
60. C. Cabaleiro-Lago et al. Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation ACS Chem. Neurosci. 1 2010 279 287
61. C. Cabaleiro-Lago et al. The effect of nanoparticles on amyloid aggregation depends on the protein stability and intrinsic aggregation rate Langmuir 28 2012 1852 1857
62. L.A. Woods et al. Ligand binding to distinct states diverts aggregation of an amyloid-forming protein Nat. Chem. Biol. 7 2011 730 739
63. S. Feng et al. Inhibition of amyloid fibrillation of lysozyme by phenolic compounds involves quinoprotein formation FEBS Lett. 586 2012 3951 3955
64. A.K. Buell et al. Probing small molecule binding to amyloid fibrils Phys. Chem. Chem. Phys. 13 2011 20044 20052
65. C. Lendel et al. On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of α-synuclein with Congo red and lacmoid Biochemistry 48 2009 8322 8334
66. A.K. Buell et al. Interactions between amyloidophilic dyes and their relevance to studies of amyloid inhibitors Biophys. J. 99 2010 3492 3497
67. M. Necula et al. Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct J. Biol. Chem. 282 2007 10311 10324
68. S.A. Hudson et al. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds FEBS J. 276 2009 5960 5972
69. G. Liu et al. Kinetic profile of amyloid formation in the presence of an aromatic inhibitor by nuclear magnetic resonance ACS Med. Chem. Lett. 3 2012 856 859
70. 1-42 peptide self-aggregation: elucidation of inhibitors' mechanism of action Chembiochem 8 2007 2152 2161
71. P. Arosio et al. Aggregation stability of a monoclonal antibody during downstream processing Pharm. Res. 28 2011 1884 1894
72. D. Brambilla et al. New method based on capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) to monitor interaction between nanoparticles and the amyloid-β peptide Anal. Chem. 82 2010 10083 10089
73. R. Carrotta et al. Protofibril formation of amyloid β-protein at low pH via a non-cooperative elongation mechanism J. Biol. Chem. 280 2005 30001 30008
74. 42 peptide aggregation by a binuclear ruthenium(II)-platinum(II) complex: potential for multimetal organometallics as anti-amyloid agents ACS Chem. Neurosci. 1 2010 691 701
75. T.P.J. Knowles et al. Kinetics and thermodynamics of amyloid formation from direct measurements of fluctuations in fibril mass Proc. Natl. Acad. Sci. U.S.A. 104 2007 10016 10021
76. A.R.A. Ladiwala et al. Aromatic small molecules remodel toxic soluble oligomers of amyloid β through three independent pathways J. Biol. Chem. 286 2011 3209 3218
77. L.Q. Xu et al. Influence of specific Hsp70 domains on fibril formation of the yeast prion protein Ure2 Philos. Trans. R. Soc. Lond. B: Biol. Sci. 368 2013 20110410
78. R. Cukalevski et al. Structural changes in apolipoproteins bound to nanoparticles Langmuir 27 2011 14360 14369
79. P. Arosio et al. Time evolution of amyloid fibril length distribution described by a population balance model Chem. Eng. Sci. 78 2012 21 32